- Home
- EAD vs CTNM Comparison
EAD vs CTNM Comparison
Compare EAD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EAD | CTNM |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.8M | 416.1M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | EAD | CTNM |
|---|---|---|
| Price | $6.79 | $11.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | 178.9K | ★ 255.0K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.69 | $3.35 |
| 52 Week High | $6.81 | $13.49 |
Technical Indicators
Market Signals| Indicator | EAD | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 58.06 |
| Support Level | $6.77 | $8.92 |
| Resistance Level | $6.89 | $11.90 |
| Average True Range (ATR) | 0.04 | 0.92 |
| MACD | 0.00 | 0.15 |
| Stochastic Oscillator | 28.57 | 79.84 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.